Opendata, web and dolomites

NovaTests

The first predictive test for radio-sensitivity. A step towards an improved and personalised radiation therapy cancer treatment.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovaTests project word cloud

Explore the words cloud of the NovaTests project. It provides you a very rough idea of what is the project "NovaTests" about.

validation    blood    vary    survivors    sensitivity    clinical    link    centre    diagnostic    trial    radio    invested    sme    indiscriminately    close    quality    significantly    prostate    damaging    biology    cells    february    79    medical    active    automating    2m    meets    sound    healthy    undergo    patient    tolerance    lung    cancers    validate    intend    therapy    accuracy    radiation    rest    tailor    treatments    90    stage    market    ongoing    unmet    cancer    tumour    5m    marking    predictive    treatment    breast    reliability    tissues    first    ce    week    fits    vitro    plan    move    time    lives    extension    radiotherapy    each    reg    fast    novagray    run    measuring    analysing    prove    direct    serious    evidences    financial    pertaining    sensitive    scientific    2016    million    regulatory    organs    patients    directive    98    efficient    radiosensitivity    deployment    robustness    tests    novatests    stamped    instrument    efficiency   

Project "NovaTests" data sheet

The following table provides information about the project.

Coordinator
NOVAGRAY 

Organization address
address: ROND POINT BENJAMIN FRANKLIN CAP OM CS 39521
city: MONTPELLIER
postcode: 34960
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.nova-gray.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NOVAGRAY FR (MONTPELLIER) coordinator 50˙000.00

Map

 Project objective

Each year, two out of three cancer patients undergo radiation therapy, meaning close to 1.5M patients in Europe and 2M in the US. However, scientific evidences prove a direct link between radiation therapy and several serious late effects. This because patient’s tolerance to radiation vary significantly and radiotherapy affects indiscriminately both healthy and cancer cells, damaging also active working cells, tissues or organs around the tumour. There is, therefore, an unmet clinical need to tailor treatments to each patient’s unique biology. NovaTests are the first predictive radio-sensitivity tests for cancer treatment. By analysing a simple blood sample, in one week time, we can determine with high accuracy (over 90%) not only whether a patient is sensitive or not to radiation but also how sensitive the patient is. We allow for more efficient treatments and improved quality of cancer survivors, not only during radiation treatments but for the rest of their lives. Our first test, the NovaGray Breast® is aimed at measuring radiosensitivity for breast cancer patients. It meets all regulatory requirements of the 98/79 directive pertaining to the in-vitro diagnostic medical devices, has been stamped with the CE marking in February 2016. So far, €0.5M million have been invested into the development and testing of technology to ensure its robustness and efficiency and move into the next stage of tests development and validation. Within the overall project, we intend to scale-up the process by automating it and run a multi-centre clinical trial to validate the reliability of the test. Further ongoing developments include the extension of the technology to prostate and lung cancers. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of NovaTests and their market uptake.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVATESTS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVATESTS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

PAROST (2019)

Disruptive technology for the identification, quantification and prediction of the evolution of damages in civil engineering structures that increases safety while reducing maintenance costs.

Read More